Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

  • Technology appraisal guidance
  • TA1085
  • Published: 
  • Last updated: 

History

Documents created during the development process.

Guidance published

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6372

Topic selection